Asabys Partners Leads €10 Million Extension of SafeHeal’s Oversubscribed Series C Financing to Accelerate Commercialization of Colovac®
Asabys joins SafeHeal’s global investor syndicate, which includes Sofinnova, Solar Eclipse and a Leading Multinational Life Sciences Corporation, bringing additional resources and strategic expertise to advance pivotal U.S. trial and commercial launch of Colovac®, SafeHeal’s breakthrough alternative to temporary stoma for colorectal cancer patients
BARCELONA, Spain and PARIS and TAMPA, Fla., Sept. 10, 2025 (GLOBE NEWSWIRE) — SafeHeal®, a medical device innovator transforming colorectal surgery, today announced a €10 million extension of its oversubscribed €35 million Series C financing round. The extension is led by Asabys Partners through its Sabadell Asabys II fund, which joins a world-leading syndicate that includes Sofinnova Partners, Solar Eclipse, Gideon Strategic Partners, Polis, M&L Healthcare, and one of the world’s largest multinational life sciences corporations. Gideon Strategic Partners, an existing investor, has also increased its participation in this extension.
The new capital raise will further accelerate SafeHeal’s pivotal U.S. IDE study and support the planned commercial launch of Colovac® in the EU. Colovac is SafeHeal’s groundbreaking temporary endoluminal bypass device, designed to eliminate the need for a temporary stoma in most patients undergoing colorectal cancer resection, improving patient recovery, outcomes and quality of life.
